Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%

This study has been completed.
Sponsor:
Information provided by:
Innovative Medical
ClinicalTrials.gov Identifier:
NCT00377546
First received: September 14, 2006
Last updated: September 23, 2008
Last verified: September 2008
  Purpose

To compare the penetration of three different NSAIDs.


Condition Intervention Phase
Vitrectomy
Drug: Nepafenac
Drug: Ketorolac LS, Bromfenac
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

  Eligibility

Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Males or females scheduled to undergo Vitrectomy surgery
  • Likely to complete all study visits and able to provide informed consent
  • Visual potential of 20/25 or better

Exclusion Criteria:

  • Known contraindications to any study medication or ingredients
  • Active ocular diseases or uncontrolled systemic disease
  • Active ocular allergies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00377546

Locations
United States, Massachusetts
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Jeffrey Heier, MD Ophthalmic Consultants of Boston
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00377546     History of Changes
Other Study ID Numbers: 5264
Study First Received: September 14, 2006
Last Updated: September 23, 2008
Health Authority: United States: Institutional Review Board

Keywords provided by Innovative Medical:
Retinal Surgery

Additional relevant MeSH terms:
Bromfenac
Ketorolac
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Central Nervous System Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014